[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340118-105":59,"doc-detail-340118-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","strategies-for-engineering-oncolytic-viruses-to-enhance-cancer-immunotherapy","Strategies for engineering oncolytic viruses to enhance cancer immunotherapy","","Non-small cell lung cancer (NSCLC) is the most common lung cancer type and is driven by a rapidly evolving tumor microenvironment that can limit the effectiveness of anti-PD-1 immune checkpoint inhibitors. This review summarizes different oncolytic virus strains used in NSCLC models and the gene edits applied to pre-existing viruses. It proposes engineering strategies to improve anti-PD-1 responses by outlining genomic adaptations for NSCLC targeting, identifying determinants of response variability, and recommending genomic modifications to strengthen therapeutic performance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/strategies-for-engineering-oncolytic-viruses-to-enhance-cancer-immunotherapy/340118/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/strategies-for-engineering-oncolytic-viruses-to-enhance-cancer-immunotherapy/340118.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is anti-PD-1 therapy less consistently effective in NSCLC?","Question",{"text":112,"@type":113},"NSCLC exhibits substantial heterogeneity in its tumor microenvironment, which strongly influences how well anti-PD-1 immune checkpoint inhibitors work. As a result, patient responses vary across individuals.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the review cover regarding oncolytic viruses in NSCLC?",{"text":117,"@type":113},"The review characterizes different strains of oncolytic viruses applied to NSCLC and summarizes gene edits introduced into pre-existing oncolytic viruses to improve function.",{"name":119,"@type":110,"acceptedAnswer":120},"How do engineered oncolytic viruses aim to enhance anti-PD-1 treatment?",{"text":121,"@type":113},"By providing a theoretically designed oncolytic virus with a detailed genomic framework, the approach targets genomic adaptations for NSCLC and proposes edits to strengthen anti-PD-1 response effectiveness and overcome variability.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340118,1790155230,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","TYPE Review  \nPUBLISHED 06 September 2024 DOI 10.3389/fphar.2024.1450203  \nOPEN ACCESS  \nEDITED BY  \nChunbo He,  \nUniversity of Oklahoma Health Sciences Center, United States  \nREVIEWED BY  \nGullanki Naga Venkata Charan Tej,  \nUniversity of Oklahoma Health Sciences Center, United States  \nJunzhang Zhao,  \nThe Sixth Afﬁliated Hospital of Sun Yat-sen University, China  \n*CORRESPONDENCE  \nZhengfeng Wang,  \n [fccwangzf1@zzu.edu.cn](fccwangzf1@zzu.edu.cn)  \nRECEIVED 17 June 2024  \nACCEPTED 30 July 2024  \nPUBLISHED 06 September 2024  \nCITATION  \nYin ZS and Wang Z (2024) Strategies for engineering oncolytic viruses to enhance cancer immunotherapy.  \nFront. Pharmacol. 15:1450203 .  \ndoi: 10.3389/fphar.2024.1450203  \nCOPYRIGHT  \n© 2024 Yin and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nStrategies for engineering oncolytic viruses to enhance cancer immunotherapy  \nZiyang (Steve) Yin 1 and Zhengfeng Wang 2*  \n1Concordia International School Shanghai, Shanghai, China, 2Department of Hepatobiliary Surgery, The First Afﬁliated Hospital of Zhengzhou University, Zhengzhou, China  \nNon-small cell lung cancer (NSCLC) is the predominant form of lung cancer and is characterized by rapid metastasis and high mortality, presenting a challenge for early-stage treatment modalities. The heterogeneity of NSCLC’s tumor microenvironment (TME) signiﬁcantly inﬂuences the efﬁcacy of anti-PD- 1 immune checkpoint inhibitors (ICIs) therapy, leading to varied patient responses. This review characterized different strains of oncolytic viruses in NSCLC and the different gene edits in pre-existing oncolytic viruses. This study also aimed to provide strategies to enhance anti-PD-1 therapy in NSCLC by engineering oncolytic viruses (OVs) . This study offers insights into the genomic adaptations necessary for OVs targeting NSCLC, identify genetic determinants of anti-PD-1 response variability, and propose genomic edits to bolster therapy effectiveness. The primary goal of this study is to present a theoretically designed OV with a detailed genomic framework capable of enhancing the response to anti-PD-1 therapy, thereby advancing the ﬁeld of cancer immunotherapy.  \nKEYWORDS  \nnon-small cell lung cancer, immune checkpoint inhibitors, oncolytic viruses, cancer immunotherapy, tumor microenvironment  \n1 Introduction  \nLung cancer ranks as the second most commonly diagnosed cancer globally, with 2.2 million new cases reported in 2020, accounting for 11.4% of all new cancer diagnoses. It is also the leading cause of cancer-related deaths, with an estimated 1.8 million fatalities per year (Sung et al., 2021) . Lung cancer can be split into two types, small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC is the more deadly of the two lung cancer types—with a 5-year survival rate of 7%—while NSCLC is less deadly but the more common of the two (85%) (Wang et al., 2020; ACS, 2022) . According to NSCLC can be further grouped into lung adenocarcinomas (40%), squamous cell carcinoma (25%–30%), and large cell carcinoma (10%–15%) (UK, 2022) .  \nSurgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy are the most common approaches to treat lung cancer. The application of these treatments depends on the stage of cancer the tumor is in upon diagnosis. For stage I and II NSCLC patients, surgical resection is the primary and preferable treatment (Howington et al., 2013) . Additionally, neoadjuvant and adjuvant chemotherapy has been approved before and following the resection of stage II or III NSCLCs to increase survival rates (Lackey and Doning","cbCaigmhzCdif0Uj","https://ap.wps.com/l/cbCaigmhzCdif0Uj","pdf",4644824,"English","# Introduction\n## NSCLC background and treatment landscape\n## Immunotherapy challenges and the role of tumor microenvironment\n# Strategies for engineering oncolytic viruses\n## Viral strains in NSCLC\n## Gene edits to enhance anti-PD-1 therapy\n# Genomic framework and proposed edits\n## Genomic adaptations for NSCLC targeting\n## Determinants of response variability\n## Proposed genomic modifications","[{\"question\":\"Why is anti-PD-1 therapy less consistently effective in NSCLC?\",\"answer\":\"NSCLC exhibits substantial heterogeneity in its tumor microenvironment, which strongly influences how well anti-PD-1 immune checkpoint inhibitors work. As a result, patient responses vary across individuals.\"},{\"question\":\"What does the review cover regarding oncolytic viruses in NSCLC?\",\"answer\":\"The review characterizes different strains of oncolytic viruses applied to NSCLC and summarizes gene edits introduced into pre-existing oncolytic viruses to improve function.\"},{\"question\":\"How do engineered oncolytic viruses aim to enhance anti-PD-1 treatment?\",\"answer\":\"By providing a theoretically designed oncolytic virus with a detailed genomic framework, the approach targets genomic adaptations for NSCLC and proposes edits to strengthen anti-PD-1 response effectiveness and overcome variability.\"}]","Strategies for engineering oncolytic viruses to enhance cancer immunotherapy | PDF",1790034273,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5518dcfdaf036318ad8ea8ca1db45c82.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b0b32dc3e297880109dde3fd5fe4bef.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/775bf9fd67fab40a509cfee09ff6d3d1.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33b4aee693c7ef1c09022144279e0dc5.webp",980,1385]